|
COPS4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.84610000012009E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.19619999999965E-06 |
| Normal-vs-Stage2 |
5.817600E-02 |
| Normal-vs-Stage3 |
7.3455000004774E-07 |
| Normal-vs-Stage4 |
1.62900004596622E-09 |
| Stage1-vs-Stage2 |
1.329450E-01 |
| Stage1-vs-Stage3 |
1.834390E-01 |
| Stage1-vs-Stage4 |
2.380500E-03 |
| Stage2-vs-Stage3 |
2.300200E-02 |
| Stage2-vs-Stage4 |
1.137240E-03 |
| Stage3-vs-Stage4 |
1.230820E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.77709999996212E-07 |
| Normal-vs-AfricanAmerican |
1.467520E-02 |
| Normal-vs-Asian |
4.38090000000058E-05 |
| Caucasian-vs-AfricanAmerican |
3.161200E-01 |
| Caucasian-vs-Asian |
8.615600E-01 |
| AfricanAmerican-vs-Asian |
4.081800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.81359999982401E-07 |
| Normal-vs-Female |
2.16100000000052E-05 |
| Male-vs-Female |
1.295810E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.63560000005148E-06 |
| Normal-vs-Age(41-60Yrs) |
4.87829999995526E-06 |
| Normal-vs-Age(61-80Yrs) |
2.35759999999141E-05 |
| Normal-vs-Age(81-100Yrs) |
3.748600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.501800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.939800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.742200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.865400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.003200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.589600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.029200E-04 |
| Classical-VS-Follicular |
8.896200E-02 |
| Classical-VS-Other |
1.954820E-01 |
| Classical-VS-Normal |
1.11020000004292E-06 |
| Tall-VS-Follicular |
9.70510000000147E-05 |
| Tall-VS-Other |
9.173200E-01 |
| Tall-VS-Normal |
1.38569999919014E-09 |
| Follicular-VS-Other |
1.438410E-01 |
| Follicular-VS-Normal |
2.076200E-02 |
| Other-VS-Normal |
9.151000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.10730000000226E-05 |
| Normal-vs-N1 |
7.52700124451167E-11 |
| N0-vs-N1 |
1.779400E-04 |
|
|
